Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?

Bristol-Myers Squibb and AstraZeneca are reportedly discussing a potential megamerger to increase their scale. In the Big Pharma sector, greater mass is viewed as an advantage, as enlarged balance sheets enable companies to make larger investments in potential blockbuster drugs. This strategic move aims to strengthen their market positions by leveraging combined resources to fund high-stakes research and development, addressing the reality that even current industry giants may find their size insufficient.